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Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus
Results of the OPTIMUS-5 Study 
HIGHLIGHTS
Vorapaxar reduces thrombotic cardiovascular events in patients with atherosclerotic disease, with enhanced effects in those with DM.
Adjunctive vorapaxar therapy reduces platelet-mediated thrombogenicity without affecting clot kinetics in both patients with and those without DM having prior MI/PAD on dual antiplatelet therapy with aspirin and clopidogrel.
The pharmacodynamic effects of vorapaxar occur via selective blockade of the PAR-1 on the platelet membrane without apparent interplay with other platelet signaling pathways.
Aspirin withdrawal, which leaves patients on a background of clopidogrel and vorapaxar, increases markers specific to COX-1-mediated blockade, leading to an increase in platelet-mediated global thrombogenicity, particularly among patients with DM.
Franchi et al.
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SUMMARY
Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown.
Moreover, although withdrawal of aspirin has emerged as a bleeding reduction strategy, the PD effects of stopping aspirin in patients treated with vorapaxar also are unknown. In this prospective PD investigation, vorapaxar was associated with reduced platelet-mediated thrombogenicity without affecting clot kinetics irrespective of DM status. However, platelet-mediated thrombogenicity increased after aspirin withdrawal, (2) . Of note, thrombin is the most potent inducer of platelet activation and plays a key role in thrombus formation (5, 6) .
Hence, modulating the effects of thrombin represents an attractive option to reduce the risk of thrombotic complications, particularly in high-risk patients such as those with DM (7).
Vorapaxar is a novel, orally active, highly selective, competitive, slowly reversible protease-activated receptor (PAR)-1 inhibitor, which exerts potent inhibition of thrombin-mediated platelet aggregation (7) (8) (9) . (patients with and without DM), a total of 56 patients with valid primary endpoint data needed to be included. Assuming up to 40% rate of invalid results due to hemolysis or dropout, we estimated that up to 79 patients would need to be enrolled. Noninferiority was assessed using a 95% CI of the difference in mean MPA between the 2 arms. As there were no preliminary data in this setting, the 10% noninferiority margin was arbitrarily defined. Mean values of platelet aggregation and variability were estimated based on previous data of vorapaxar (26) Franchi et al. 
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Vorapaxar and Diabetes (hematuria) while on triple therapy that led to study drug discontinuation, and 11 patients (7 with DM, 4 without DM) had nonbleeding adverse events (see Supplemental Material for details). there were no significant differences in levels of these Franchi et al.
PD FINDINGS. E f f e c t s o f v o r a p a x a r o n t h r o m b i nm e d i a t e d e f f e c t s .
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